Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2024-01-30 Purchase | 2024-03-06 9:52 pm | Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | 190 | $3.595 | $683 | 819,590 (Direct) | View |
2023-12-18 Sale | 2023-12-20 4:26 pm | Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director | 18,640 | $2.6994 | $50,317 | 62,456 (Direct) | View |
2023-08-07 Sale | 2023-08-09 4:07 pm | Allogene Therapeutics Inc. | ALLO | Mayo Stephen Director | 10,000 | $4.2855 | $42,855 | 25,328 (Direct) | View |
2023-02-13 Sale | 2023-02-14 5:10 pm | Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel | 3,000 | $6.85 | $20,550 | 577,677 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-04-22 Tax Withholding | 2024-04-24 4:18 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | MOORE TIMOTHY L. Chief Technical Officer | 17,360 | $3.4671 | 265,459 (Direct) | View |
2024-03-14 Tax Withholding | 2024-03-18 8:10 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO | 53,393 | $4.33 | 7,378,474 (Direct) | View |
2024-01-25 Option Award | 2024-01-31 5:51 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | MOORE TIMOTHY L. Chief Technical Officer | 438,115 | $0 | 624,334 (Direct) | View |
2024-01-25 Option Award | 2024-01-31 5:48 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | Douglas Earl Martin SVP, General Counsel | 189,578 | $0 | 625,412 (Direct) | View |
2024-01-25 Option Award | 2024-01-31 5:47 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | 133,339 | $0 | 923,339 (Direct) | View |
2024-01-25 Option Award | 2024-01-31 5:46 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director | 961,371 | $0 | 9,319,579 (Direct) | View |
2024-01-25 Option Award | 2024-01-31 5:45 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D | 634,949 | $0 | 1,010,202 (Direct) | View |
2024-01-25 Option Award | 2024-01-31 5:42 pm | N/A 2034-01-25 | Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO | 1,441,335 | $0 | 8,549,934 (Direct) | View |
2024-01-22 Tax Withholding | 2024-01-24 5:25 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D | 24,690 | $3.1744 | 375,253 (Direct) | View |
2023-10-16 Option Award | 2023-10-17 5:02 pm | N/A 2033-10-16 | Allogene Therapeutics Inc. | ALLO | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | 1,740,000 | $0 | 1,740,000 (Direct) | View |
2023-08-14 Option Award | 2023-08-17 6:57 pm | N/A 2033-08-14 | Allogene Therapeutics Inc. | ALLO | Douglas Earl Martin GENERAL COUNSEL | 1,396,688 | $0 | 1,396,688 (Direct) | View |
2023-08-10 Option Award | 2023-08-14 7:59 pm | N/A 2033-08-10 | Allogene Therapeutics Inc. | ALLO | CHEN YINLIN JACK SVP, Finance | 50,561 | $0 | 128,041 (Direct) | View |
Ownership | 2023-08-14 7:28 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | CHEN YINLIN JACK SVP, Finance | 0 | $0 | 272,725 (Direct) | View |
2023-06-13 Option Award | 2023-06-15 5:06 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | MESSEMER DEBORAH M. Director | 74,561 | $0 | 81,096 (Direct) | View |
2023-06-13 Option Award | 2023-06-15 5:03 pm | N/A 2033-06-13 | Allogene Therapeutics Inc. | ALLO | Barrett Elizabeth A. Director | 116,120 | $0 | 116,120 (Direct) | View |
2023-06-13 Option Award | 2023-06-15 5:02 pm | N/A 2033-06-13 | Allogene Therapeutics Inc. | ALLO | SATO VICKI L Director | 82,873 | $0 | 124,324 (Direct) | View |
2023-06-13 Option Award | 2023-06-15 5:01 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Humer Franz B Director | 74,561 | $0 | 266,453 (Direct) | View |
2023-06-13 Option Award | 2023-06-15 5:00 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | WITTE OWEN N. Director | 74,561 | $0 | 292,832 (Direct) | View |
2023-06-13 Option Award | 2023-06-15 4:57 pm | N/A 2033-06-13 | Allogene Therapeutics Inc. | ALLO | Mayo Stephen Director | 116,120 | $0 | 116,120 (Direct) | View |
2023-06-13 Option Award | 2023-06-15 4:56 pm | N/A 2033-06-13 | Allogene Therapeutics Inc. | ALLO | Kazam Joshua A Director | 116,120 | $0 | 116,120 (Direct) | View |
2023-04-24 Option Award | 2023-04-26 5:20 pm | N/A 2033-04-24 | Allogene Therapeutics Inc. | ALLO | MOORE TIMOTHY L. Chief Technical Officer | 1,017,243 | $0 | 1,017,243 (Direct) | View |
2023-04-03 Option Award | 2023-04-05 6:43 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Smith Lillian VP, Corporate Counsel | 56,545 | $0 | 140,390 (Direct) | View |
Ownership | 2023-04-05 6:38 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Smith Lillian VP, Corporate Counsel | 0 | $0 | 229,674 (Direct) | View |
2023-03-22 Option Award | 2023-03-24 8:19 pm | N/A 2033-03-22 | Allogene Therapeutics Inc. | ALLO | MOORE ALISON Chief Technical Officer | 990,832 | $0 | 1,105,469 (Direct) | View |
2023-03-22 Option Award | 2023-03-24 8:17 pm | N/A 2033-03-22 | Allogene Therapeutics Inc. | ALLO | SCHMIDT ERIC THOMAS Chief Financial Officer | 990,832 | $0 | 2,447,772 (Direct) | View |
2023-03-22 Option Award | 2023-03-24 8:16 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D | 148,035 | $0 | 399,943 (Direct) | View |
2023-03-22 Option Award | 2023-03-24 8:14 pm | N/A 2033-03-22 | Allogene Therapeutics Inc. | ALLO | Belldegrun Arie Director | 2,277,776 | $0 | 9,353,008 (Direct) | View |
2023-03-22 Option Award | 2023-03-24 8:13 pm | N/A 2033-03-22 | Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO | 3,416,664 | $0 | 8,599,307 (Direct) | View |
2023-03-14 Tax Withholding | 2023-03-16 5:32 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Chang David D President and CEO | 22,340 | $5.56 | 5,182,643 (Direct) | View |
2023-03-14 Tax Withholding | 2023-03-16 5:08 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | SCHMIDT ERIC THOMAS Chief Financial Officer | 35,879 | $5.47 | 1,456,940 (Direct) | View |
2023-03-14 Tax Withholding | 2023-03-16 4:49 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | MOORE ALISON Chief Technical Officer | 8,351 | $5.5071 | 114,637 (Direct) | View |
2023-03-14 Tax Withholding | 2023-03-16 4:46 pm | N/A N/A | Allogene Therapeutics Inc. | ALLO | Bhavnagri Veer General Counsel | 23,628 | $5.67 | 556,049 (Direct) | View |
2023-01-20 Option Award | 2023-01-24 5:02 pm | N/A 2033-01-20 | Allogene Therapeutics Inc. | ALLO | Roberts Zachary EVP of R&D | 1,124,923 | $0 | 1,124,923 (Direct) | View |